Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06246149 · ClinicalTrials.gov registry record · Phase 3
Adjuvant Tebentafusp in High Risk Ocular Melanoma
A Phase 3 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
NCT06246149 is a Phase 3 study that is actively recruiting participants, run by European Organisation for Research and Treatment of Cancer - EORTC. The registered enrollment target is 290 participants.
The verdict
NCT06246149, a Phase 3 study, is actively recruiting participants, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
Study Summary
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.
Interventions
- DRUG Tebentafusp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2032-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06246149
The ClinicalTrials.gov registry entry for NCT06246149 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tebentafusp is the first listed.
NCT06246149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06246149 about?
NCT06246149 is a clinical study titled "Adjuvant Tebentafusp in High Risk Ocular Melanoma". At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastat...
What is the current status of trial NCT06246149?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 290 participants. The study started on 2024-11-11. Estimated completion is 2032-11.
What interventions are being tested in trial NCT06246149?
The interventions under investigation include: Tebentafusp (DRUG).
Who is sponsoring clinical trial NCT06246149?
This trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.